X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2019 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
XFOR on Nasdaq
Shares outstanding
7,938,059
Price per share
$3.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
2,507,092
Total reported value
$8,574,256
% of total 13F portfolios
0%
Share change
+1,853,803
Value change
+$6,340,006
Number of holders
2
Price from insider filings
$3.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 4.8% $1,722,190 8,200,903 The Vanguard Group 31 Dec 2024
ORBIMED ADVISORS LLC 1.7% $25,640 134,947 ORBIMED ADVISORS LLC 30 Jun 2025

As of 30 Sep 2025, 2 institutional investors reported holding 2,507,092 shares of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR). This represents 32% of the company’s total 7,938,059 outstanding shares.

Top 2 Institutional Shareholders

The largest institutional shareholders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
NEA Management Company, LLC 28% 2,233,743 +347% 0.42% $7,639,401
ACORN CAPITAL ADVISORS, LLC 3.4% 273,349 +78% 0.47% $934,855

Institutional Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 2,507,092 $8,574,256 +$6,340,006 $3.42 2
2025 Q2 653,289 $1,241,249 -$59,123,513 $1.90 2
2025 Q1 98,484,813 $23,301,506 -$1,452,436 $0.24 91
2024 Q4 99,822,228 $73,237,598 -$4,976,811 $0.73 89
2024 Q3 100,589,647 $67,320,286 -$551,331 $0.67 99
2024 Q2 101,525,161 $58,892,214 -$4,474,588 $0.58 99
2024 Q1 102,998,180 $143,154,095 +$8,938,947 $1.39 97
2023 Q4 49,260 $41,305 $0.84 1
2023 Q3 112,411,447 $122,530,520 -$3,785,069 $1.09 89
2023 Q2 112,917,632 $219,060,015 +$104,255,275 $1.94 94
2023 Q1 60,975,055 $53,048,929 +$698,181 $0.87 55
2022 Q4 60,609,655 $60,186,243 +$20,622,188 $0.99 50
2022 Q3 39,071,809 $66,811,950 +$39,533,196 $1.71 50
2022 Q2 16,040,519 $15,514,241 -$673,648 $0.96 42
2022 Q1 16,339,188 $28,595,538 -$2,236,337 $1.75 51
2021 Q4 17,568,471 $40,229,950 -$2,281,727 $2.29 49
2021 Q3 16,206,423 $85,728,624 -$2,790,984 $5.29 50
2021 Q2 16,587,665 $107,777,003 +$941,220 $6.50 60
2021 Q1 16,127,455 $138,726,293 +$48,886,704 $8.61 60
2020 Q4 9,742,672 $62,643,946 +$1,445,508 $6.43 51
2020 Q3 9,514,235 $64,412,392 -$4,897,995 $6.77 49
2020 Q2 10,686,184 $99,586,639 -$2,650,048 $9.32 53
2020 Q1 11,238,083 $112,377,520 +$1,376,789 $10.00 48
2019 Q4 11,024,149 $117,956,922 +$34,778,222 $10.70 52
2019 Q3 7,712,195 $98,016,473 +$1,604,023 $12.71 47
2019 Q2 7,583,356 $113,750,545 +$86,908,619 $15.00 42
2019 Q1 1,788,579 $31,136,000 +$31,136,025 $17.41 28